Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Benzinga Newsdesk 11 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10
– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –
– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10 mmol/L) and at high risk of developing acute pancreatitis –
